0.00

100.00% -0.661

Acorda Therapeutics Inc (ACOR)

Overview News Price History Discussions Forecast Stock Split

Acorda Therapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.7075 pivot point. If it approaches the $0.3267 support level, significant changes may occur.

Previous Close:

$0.661

Open:

24h Volume:

Market Cap:

$821.03K

Revenue:

$117.63M

Net Income/Loss:

$-252.85M

P/E Ratio:

0.00

EPS:

-21.35

Net Cash Flow:

$-14.25M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1D Range:

$0.00

52W Range:

$0.00

$18.20

Acorda Therapeutics Inc Stock (ACOR) Company Profile

Name

Acorda Therapeutics Inc

Sector

Healthcare (1201)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

914 347 4300

Address

420 Saw Mill River Road, Ardsley, NY

Employee

Twitter

@acordanews

Next Earnings Date

2024-05-02

Latest SEC Filings

ACOR's Discussions on Twitter

Acorda Therapeutics Inc Stock (ACOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-21	Upgrade	H.C. Wainwright	Neutral → Buy
Aug-14-19	Downgrade	H.C. Wainwright	Buy → Neutral
May-23-19	Initiated	Wedbush	Neutral
Dec-11-18	Downgrade	Goldman	Neutral → Sell
Aug-07-18	Reiterated	Stifel	Hold
Feb-16-18	Upgrade	Piper Jaffray	Neutral → Overweight
Jan-17-18	Reiterated	H.C. Wainwright	Buy
Nov-28-17	Resumed	Piper Jaffray	Neutral
Nov-16-17	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-16-17	Downgrade	Stifel	Buy → Hold
Nov-09-17	Initiated	Oppenheimer	Perform
Nov-08-17	Initiated	H.C. Wainwright	Buy
Oct-06-17	Resumed	Goldman	Sell
Jul-11-17	Initiated	Jefferies	Hold
Apr-03-17	Downgrade	JP Morgan	Overweight → Neutral
Feb-15-17	Upgrade	Goldman	Sell → Neutral
Nov-30-16	Upgrade	JP Morgan	Neutral → Overweight
Oct-04-16	Resumed	Leerink Partners	Mkt Perform
Mar-30-16	Initiated	Goldman	Sell
Sep-01-15	Initiated	Raymond James	Mkt Perform
Jun-09-15	Initiated	Guggenheim	Neutral

View All

Acorda Therapeutics Inc Stock (ACOR) Latest News

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Benzinga

Nasdaq Down Over 1%; VivoPower International Shares Spike Higher

Benzinga

Acorda Therapeutics Inc Stock (ACOR) Financials Data

Acorda Therapeutics Inc (ACOR) Revenue 2024

ACOR reported a revenue (TTM) of $117.63 million for the quarter ending December 31, 2023, a -0.79% decline year-over-year.

Acorda Therapeutics Inc (ACOR) Net Income 2024

ACOR net income (TTM) was -$252.85 million for the quarter ending December 31, 2023, a -283.60% decrease year-over-year.

Acorda Therapeutics Inc (ACOR) Cash Flow 2024

ACOR recorded a free cash flow (TTM) of -$14.25 million for the quarter ending December 31, 2023, a +32.35% increase year-over-year.

Acorda Therapeutics Inc (ACOR) Earnings per Share 2024

ACOR earnings per share (TTM) was -$203.83 for the quarter ending December 31, 2023, a -124.53% decline year-over-year.

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.